16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom Two additional countries expected to be added in the coming months AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The Company announced that the first patient has been randomized in the United Kingdom, marking another milestone in the ongoing expansion of the Phase 2 RENEW clinical trial.